Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Dembek, Claudia J ^a   Kutscher, Sarah ^a   Heltai, Silvia ^b   Allgayer, Simone ^a,c   Biswas, Priscilla ^b   Ghezzi, Silvia ^b   Vicenzi, Elisa ^b   Hoffmann, Dieter ^c   Reitmeir, Peter ^a   Tambussi, Giuseppe ^b   Bogner, Johannes R ^d   Lusso, Paolo ^b   Stellbrink, Hans J ^e   Santagostino, Elena ^f   Vollbrecht, Thomas ^d   Goebel, Frank D ^d   Protzer, Ulrike ^a,c   Draenert, Rika ^d   Tinelli, Marco ^g   Poli, Guido ^b,h   Erfle, Volker ^a   Malnati, Mauro ^b   Cosma, Antonio ^a   more..

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Infektionsmedizinisches Centrum Hamburg   (Germany)

^f UNIVERSITY OF MILAN   (Italy)

^g Hospital of Lodi   (Italy)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEF PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CD45RA+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SECRETION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EFFECTOR CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION CONTROL; LYMPHOCYTE FUNCTION; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REBOUND; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRUS REPLICATION;

EID: 77954079577     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-20     Document Type: Article

References (42)

1. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 1998, 72:164-169. 109361, 9420212.
2. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999, 189:991-998. 10.1084/jem.189.6.991, 2193038, 10075982.
3. O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, Gonzalez EJ, Jacoby TJ, Yant L, Piontkivska H, Pantophlet R, et al. A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 2004, 78:14012-14022. 10.1128/JVI.78.24.14012-14022.2004, 533930, 15564508.
4. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'Sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, et al. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 2005, 79:13239-13249. 10.1128/JVI.79.21.13239-13249.2005, 1262562, 16227247.
5. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000, 97:2709-2714. 10.1073/pnas.050567397, 15994, 10694578.
6. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752. 10.1126/science.283.5408.1748, 10073943.
7. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, Sabbaghian MS, Ehler L, Prussin C, Stevens R, Lambert L, et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol 2000, 165:1082-1092.
8. Betts MR, Ambrozak DR, Douek DC, Bonhoeffer S, Brenchley JM, Casazza JP, Koup RA, Picker LJ. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001, 75:11983-11991. 10.1128/JVI.75.24.11983-11991.2001, 116093, 11711588.
9. Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol 2004, 78:3233-3243. 10.1128/JVI.78.7.3233-3243.2004, 371059, 15016844.
10. Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007, 23:67-76. 10.1089/aid.2006.0114, 17263635.
11. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004, 4:648-655. 10.1038/nri1416, 15286731.
12. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006, 211:236-254. 10.1111/j.0105-2896.2006.00395.x, 16824132.
13. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789. 10.1182/blood-2005-12-4818, 1895811, 16467198.
14. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2007, 2:e321. 10.1371/journal.pone.0000321, 1824710, 17389912.
15. Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, Klenerman P, Nixon DF, Michaelsson J. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point. J Virol 2007, 81:5759-5765. 10.1128/JVI.00045-07, 1900265, 17376902.
16. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, Karrer U, Oxenius A. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 2008, 82:3391-3404. 10.1128/JVI.02383-07, 2268491, 18199637.
17. Wei BL, Arora VK, Foster JL, Sodora DL, Garcia JV. In vivo analysis of Nef function. Curr HIV Res 2003, 1:41-50. 10.2174/1570162033352057, 15043211.
18. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Butto S, Monini P, Magnani M, Caputo A, Garaci E. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. Aids 2006, 20:2245-2261. 10.1097/QAD.0b013e3280112cd1, 17117011.
19. Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldrige RL, van Lunzen J, Stellbrink HJ, et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004, 363:863-866. 10.1016/S0140-6736(04)15735-8, 15031033.
20. Chattopadhyay PK, Yu J, Roederer M. Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression. Nat Protoc 2006, 1:1-6. 10.1038/nprot.2006.1, 17406204.
21. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135. 10.1146/annurev.immunol.16.1.111, 9597126.
22. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712. 10.1038/44385, 10537110.
23. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002, 8:379-385. 10.1038/nm0402-379, 11927944.
24. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, Appay V, Rizzardi GP, Fleury S, Lipp M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001, 410:106-111. 10.1038/35065118, 11242051.
25. Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008, 5:e100. 10.1371/journal.pmed.0050100, 2365971,2365971, 18462013.
26. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13:46-53. 10.1038/nm1520, 17173051.
27. Brumme ZL, Brumme CJ, Heckerman D, Korber BT, Daniels M, Carlson J, Kadie C, Bhattacharya T, Chui C, Szinger J, et al. Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog 2007, 3:e94. 10.1371/journal.ppat.0030094, 1904471,1904471, 17616974.
28. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J, et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995, 1:1167-1173. 10.1038/nm1195-1167, 7584989.
29. Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, et al. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003, 77:7330-7340. 10.1128/JVI.77.13.7330-7340.2003, 164796, 12805431.
30. Moanna A, Dunham R, Paiardini M, Silvestri G. CD4+ T-cell depletion in HIV infection: killed by friendly fire?. Curr HIV/AIDS Rep 2005, 2:16-23. 10.1007/s11904-996-0004-3, 16091244.
31. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870. 10.1086/314660, 10068581.
32. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:83-92.
33. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy JP, Little S, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009, 83:7641-7648. 10.1128/JVI.00182-09, 2708622, 19458000.
34. Kutscher S, Dembek CJ, Allgayer S, Heltai S, Stadlbauer B, Biswas P, Nozza S, Tambussi G, Bogner JR, Stellbrink HJ, et al. The intracellular detection of MIP-1beta enhances the capacity to detect IFN-gamma mediated HIV-1-specific CD8 T-cell responses in a flow cytometric setting providing a sensitive alternative to the ELISPOT. AIDS Res Ther 2008, 5:22. 10.1186/1742-6405-5-22, 2569082, 18837993.
35. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinhoj P, Pedersen BK. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998, 177:331-336. 10.1086/514192, 9466518.
36. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815. 10.1126/science.270.5243.1811, 8525373.
37. Makedonas G, Betts MR. Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006, 28:209-219. 10.1007/s00281-006-0025-4, 16932955.
38. Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol 2003, 74:736-749. 10.1189/jlb.0403180, 12960235.
39. Biswas P, Poli G, Kinter AL, Justement JS, Stanley SK, Maury WJ, Bressler P, Orenstein JM, Fauci AS. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med 1992, 176:739-750. 10.1084/jem.176.3.739, 2119360, 1512539.
40. Vardas E, Butto S, Glashoff R, Malnati MS, Poli G, Clerici M. Preparing for phase II/III HIV vaccine trials in Africa. Microbes Infect 2005, 7:1436-1444.
41. Lamoreaux L, Roederer M, Koup R. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 2006, 1:1507-1516. 10.1038/nprot.2006.268, 17406442.
42. Casazza JP, Betts MR, Price DA, Precopio ML, Ruff LE, Brenchley JM, Hill BJ, Roederer M, Douek DC, Koup RA. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med 2006, 203:2865-2877. 10.1084/jem.20052246, 2118179, 17158960.